Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression changes in mouse kidney cancer cells (RENCA) after sunitinib resistance and acute and chronic withdrawal

ABSTRACT: Transcriptome analysis was used to identify changes in mouse kidney cancer cells (RENCA) resistant to sunitinib (SuR) and after short and long term sunitinib withdrawal in vitro (ST-W for 48 hours and LT-W for more than 2 months, respectively).

ORGANISM(S): Mus musculus

PROVIDER: GSE122821 | GEO | 2018/11/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression changes in mouse fibroblasts (3T3) after sunitinib resistance and acute and chronic withdrawal

Project description:Transcriptome analysis was used to identify changes in mouse fibroblasts (3T3) resistant to sunitinib (SuR) and after short and long term sunitinib withdrawal in vitro (ST-W for 48 hours and LT-W for more than 2 months, respectively).

2018-11-22 | GSE122820 | GEO

Gene expression changes in human breast cancer cells (LM2-4) after sunitinib resistance and chronic withdrawal

Project description:Transcriptome analysis was used to identify changes in human breast cancer cells (LM2-4) resistant to sunitinib (SuR) and after long term sunitinib withdrawal in vitro (LT-W for more than 6 months).

2018-11-22 | GSE122819 | GEO

Gene expression changes in mouse kidney cancer cells (RENCA) after sunitinib resistance and acute and chronic withdrawal

Project description:Gene expression changes in mouse kidney cancer cells (RENCA) after sunitinib resistance and acute and chronic withdrawal

| PRJNA506433 | ENA

Effect of Sunitinib treatment withdrawal on Immunodeficient mice bearing MDA-MB231 tumors

Project description:Immunodeficient RAG1-/- mice bearing MDA-MB231-LUC+ tumors of 50-70 mm3 were daily administrated by gavage with vehicle (containing, 0.5% carboxymethylcellulose, 1.8 % NaCl, 0.4 % Tween-80, 0.9 %. benzyl alcohol, and ultrapure water adjusted to pH 6.0) or sunitinib (40mg/kg/day) for 30 days followed by treatment withdrawal for 3-4 weeks to allow the tumor regrowth until reaching the same volume as that of the vehicle treated group. Mice were sacrificed when tumor reached the volume of 350-400 mm3 and RNAs of two tumors from two different mice treated with sunitinib or vehicle were extracted. One color experiment with 2 experimental conditions: Sunitinib vs Vehicle (n=2), corresponding to a total of 4 samples.

2014-08-24 | E-GEOD-50795 | biostudies-arrayexpress

Effect of Sunitinib treatment withdrawal on Immunodeficient mice bearing MDA-MB231 tumors

2014-08-24 | GSE50795 | GEO

Comparison of Renca tumor cells growing intrakidney or subcutaneously

Project description:Tumors can occur in many sites in the body, but how tissues at different anatomical sites affect tumor microenvironments and their subsequent response to therapy is not known. Here we show that different tissues can cause the same tumor to develop fundamentally different microenvironments resulting in dramatic changes in responses to immunotherapy. Whereas established subcutaneous tumors could be eradicated in the majority of mice using a combination of three agonist antibodies, tumors in visceral organs responded much less. Orthotopic kidney tumors had a microenvironment with a higher frequency of alternatively-activated macrophages and their associated molecules. Neutralizing the CCL2 chemokine or IL-13 cytokine, important in macrophage biology led to a greatly improved therapeutic effect. Importantly, a significantly reduced therapeutic response of subcutaneous tumors was observed when visceral tumors were simultaneously present in the same mice. In this study we sought to compare gene expression of mouse renal cell carcinoma cells growing in the kidney to cells growing subcutaneously. Renca is a renal cell carcinoma cell line (Murphy and Hrushesky, 1973). To produce subcutaneous tumors, mice received 2 x 10^5 Renca. Orthotopic tumors were established by first surgically isolating the organ and then injecting 2 x 10^5 Renca cells intrakidney (IK) into the outer cortex of the kidney in 20 ul of PBS. Tumors were removed from mice 12 days after implantation, when approximately 20-30 mm2. Tumors were snap frozen on liquid nitrogen prior to processing for total RNA followed by analysis on Mouse Gene 1.0 chips. Kidney Renca tumors were excised from 3 BALB/c mice and subcutaneous Renca tumors were excised from another 3 BALB/c mice. cDNA was prepared and hybridized to Mouse Gene 1.0 ST chips.

2012-09-08 | E-GEOD-40679 | biostudies-arrayexpress

Gene expression changes in mouse kidney cancer cells (RENCA) after anti-PD-L1 resistance

Project description:RNA sequencing analysis was used to identify changes in mouse kidney cancer cells (RENCA) following resistance to anti-PD-L1 (PDR).

2024-10-14 | GSE186037 | GEO

Differentially expressed genes analysis between dihydroberberine, sunitinib and dihydroberberine plus sunitinib.

2015-06-26 | GSE70282 | GEO

Differentially expressed genes analysis between dihydroberberine, sunitinib and dihydroberberine plus sunitinib.

Project description:To gain insights into the mechanisms of dihydroberberine, sunitinib and dihydroberberine plus sunitinib on inhibition to A549 cells, we have employed whole genome microarray expression profiling as a discovery platform to identify different genes between dihydroberberine, sunitinib and dihydroberberine plus sunitinib-treated sample and control. A549 cells were cultivated in the absence or presence of 25?mol/L dihydroberberine, 2?mol/L sunitinib, 25?mol/L dihydroberberine plus 2?mol/L sunitinib for 48 h, followed by the Agilent Whole Human Genome Oligo Microarray

2015-06-26 | E-GEOD-70282 | biostudies-arrayexpress

Gene expression changes in mouse fibroblasts (3T3) after sunitinib resistance and acute and chronic withdrawal

Project description:Gene expression changes in mouse fibroblasts (3T3) after sunitinib resistance and acute and chronic withdrawal

| PRJNA506430 | ENA